Treatment of refractory anemias with methenolone.
A therapeutic trial with methenolone (Primobolan) in 19 consecutive patients with different types of refractory anemia is reported. The remission frequencies were: pancytopenia 3/6, bicytopenia 2/4, refractory anemia with hyperplastic marrow 1/5, myelofibrosis 1/4. There was no obvious prolongation of survival in the patients responding. Side-effects were negligible.
D000368:Aged; D000380:Agranulocytosis / Q000188:drug therapy; D000741:Anemia, Aplastic / Q000188:drug therapy* / Q000401:mortality; D056486:Chemical and Drug Induced Liver Injury; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008099:Liver / Q000187:drug effects; D008297:Male; D008710:Methenolone / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D010198:Pancytopenia / Q000188:drug therapy; D055728:Primary Myelofibrosis / Q000188:drug therapy; D012075:Remission, Spontaneous; D014770:Virilism / Q000139:chemically induced
D008710:Methenolone